Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beyond DMD, Summit Aims For Top With Novel Antibiotics

Executive Summary

While investors will be keeping a close eye on the 48-week read-out of the Phase II trial of Summit Therapeutics’ utrophin modulator ezutromid in patients with Duchenne muscular dystrophy, expected in the third quarter, the Oxford, UK-based biotech is increasing its interest in novel antibiotics. Company CEO Glyn Edwards caught up with Scrip at the 2018 Biotech Showcase and outlined how Summit intends to take on both DMD and develop narrow spectrum antibiotics against new targets in challenging pathogens such as Clostridium difficile.


Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts